Showing 1,659 news articles about Hepatitis & HIV

Filters Content type: Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

New & experimental hepatitis C treatment

Gilead, Vertex and the Mystery of Missing Hep C Patients

Editor's pick
The Street
13 February 2012
Hepatitis C treatment

Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

Editor's pick
AIDSMeds
8 February 2012
Hepatitis C treatment

Copy of Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

Editor's pick
Kaiser Daily Global Health Policy Report
8 February 2012
Drug interactions & pharmacokinetics

Combining HCV Med Boceprevir with Boosted HIV Protease Inhibitors Can Lower Drug Levels

Editor's pick
HIVandHepatitis.com
7 February 2012
New & experimental hepatitis C treatment

Gilead Gains on Positive Data From Experimental Hepatitis C Drug

Editor's pick
Bloomberg
3 February 2012
Hepatitis C treatment

European Study Does Not See Rapid Long-Term Liver Fibrosis in HIV/HCV Coinfected People

Editor's pick
HIVandHepatitis.com
2 February 2012
Hepatitis C treatment

Alcohol Treatment Boosts Hep C Cure Rates Among Drinkers

Editor's pick
AIDSMeds.com
31 January 2012
Hepatitis B

Statins May Stave Off Liver Cancer in People With Hepatitis B

Editor's pick
Health Day
30 January 2012
Hepatitis C transmission & prevention

More must be done to reduce hepatitis C transmission amongst HIV positive gay men

Editor's pick
NAT
30 January 2012
Pharmaceutical industry

Top Hepatitis C Virus Biotech Picks By The World's Largest Fund Managers

Editor's pick
Seeking Alpha
25 January 2012
New & experimental hepatitis C treatment

Entry Point for Hepatitis C Infection Identified

Editor's pick
University of Illinois press release
25 January 2012
New & experimental hepatitis C treatment

Vertex Vows to Fight On With Alios Drugs in High-Stakes Hepatitis C Race

Editor's pick
Xconomy
25 January 2012
New & experimental hepatitis C treatment

Achillion's Hep C Pipeline Likely Can't Compete

Editor's pick
BioMed Reports
19 January 2012
Pharmaceutical industry

Bristol-Myers Raised Offer 30% to Beat Competitor for Inhibitex

Editor's pick
Bloomberg Business Week
17 January 2012
Hepatitis C symptoms & diagnosis

France: Is more frequent monitoring for liver cancer among co-infected people needed?

Editor's pick
CATIE
11 January 2012
New & experimental hepatitis C treatment

Idenix Reports Advancement of HCV Development Pipeline

Editor's pick
Idenix (press release)
11 January 2012
New & experimental hepatitis C treatment

Achillion Reports Clinical Data on Portfolio of HCV Protease Inhibitors

Editor's pick
Achillion (press release)
11 January 2012
Pharmaceutical industry

Merck Hepatitis C Drug May `Anchor' Future Worldwide Regimen

Editor's pick
Bloomberg
10 January 2012
Pharmaceutical industry

Bristol Buys Inhibitex for $2.5 Billion to Compete in Hepatitis

Editor's pick
Bloomberg BusinessWeek
9 January 2012
Hepatitis C transmission & prevention

Hepatitis C vaccine: Oxford researchers' trial 'promising'

Editor's pick
BBC
4 January 2012
HIV treatment

Top 10 HIV and Hepatitis Stories of 2011

Editor's pick
HIVandHepatitis.com
3 January 2012
Pharmaceutical industry

The Hepatitis C Market: Biotech’s Version of the Daytona 500

Editor's pick
Xconomy
13 December 2011
New & experimental hepatitis C treatment

AASLD: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV

Editor's pick
HIVandHepatitis.com
12 December 2011
Hepatitis C treatment

Poor Liver Transplant Outcomes for HIV/HCV Coinfected Patients

Editor's pick
Medscape (requires free registration)
6 December 2011